肿瘤细胞治疗研究
英文原题：γδ T cells at the interface of innate and adaptive immunity in cancer.
我们得出结论，下一代癌症治疗应在合成免疫学、个体化建模和联合治疗方案中战略性地整合γδ T细胞。
γδ T 细胞是非传统淋巴细胞，通过将不依赖经典主要组织相容性复合体分子的应激诱导配体识别与克隆扩增和长期适应的能力相结合，桥接固有免疫和适应性免疫。它们利用半恒定 T 细胞受体、butyrophilin 识别和自然杀伤样受体检测恶性转化的非凡能力，使其成为能够逃逸经典免疫逃逸机制的肿瘤中的强效效应细胞。此外，不同的 γδ 亚群具有不同的表型和特定的组织驻留性，可利用这些特性来调节免疫反应。我们评估了工程化疗法以及用于研究 γδ T 细胞生物学的不同实验平台。我们得出结论，下一代癌症治疗应战略性地将 γδ T 细胞整合到合成免疫学、个体化建模和联合方案中。
γδ T cells are unconventional lymphocytes that bridge innate and adaptive immunity by combining recognition of stress-induced ligands independently of classical major histocompatibility complex molecules with the capacity to undergo clonal expansion and long-term adaptation. Their unusual ability to detect malignant transformation using semi-invariant T-cell receptors, butyrophilin recognition and natural killer-like receptors positions them as powerful effector cells in tumors that evade classical immune escape mechanisms. Furthermore, distinct γδ subsets have distinct phenotyping and specific tissue-residencies, which could be leveraged to modulate immunological responses. We evaluate engineered therapies and different experimental platforms for studying γδ T cell biology. We conclude that next-generation cancer treatments should strategically integrate γδ T cells into synthetic immunology, individualized modeling, and combinatorial regimes.
MEMBER ACCOUNT
登录成功会直接打开下一页。
